Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Downgraded by Wall Street Zen to “Buy”

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

A number of other equities analysts have also recently commented on the company. UBS Group cut Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Bank of America downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Finally, Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Trading Down 1.2%

NYSE:FMS traded down $0.29 during trading hours on Friday, reaching $24.01. The company’s stock had a trading volume of 451,243 shares, compared to its average volume of 363,121. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.08 and a current ratio of 1.44. The firm has a market capitalization of $14.09 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 0.64 and a beta of 0.90. The firm has a 50-day simple moving average of $25.98 and a 200-day simple moving average of $26.56. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $21.06 and a 1 year high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The firm had revenue of $5.63 billion for the quarter, compared to analysts’ expectations of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%. Research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Institutional investors and hedge funds have recently modified their holdings of the stock. TD Waterhouse Canada Inc. bought a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter worth about $36,000. Brooklyn Investment Group grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% during the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock worth $32,000 after acquiring an additional 1,040 shares during the period. Atlantic Union Bankshares Corp purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 2nd quarter worth approximately $43,000. Hantz Financial Services Inc. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after acquiring an additional 1,768 shares in the last quarter. Finally, Huntington National Bank lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 219.5% in the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock valued at $67,000 after purchasing an additional 1,618 shares during the period. 8.37% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.